Mako Surgical (NSDQ:MAKO) has had a tough month on Wall Street, with shares having lost 45% since the end of April, but not everyone is running for the hills.
Earlier this week a company director, Frederick Moll, picked up another 5,000 shares at $24.15 each, representing the 1st insider buy on the open market since late last year.
MAKO shares tanked after the company reported Q1 sales of its Rio robotic surgery system that were lower than expected, sliding 36% in one day on May 8 after releasing earning on May 7.
Another director, John Savarese, sold more than 1.2 million shares at $25.23 each earlier in the month.
"This could be the time to buy," according to analyst Jonathan Yates, who writes for SmallCap Network, pointing to the company’s non-existent long-term debt and 5-year sales growth of about 325%.
BSD Medical goes direct
BSD Medical Corp. (NSDQ:BSDM) launched its new direct sales program for the MicroThermX microwave ablation system for major metropolitan areas in the U.S. The company hopes to capitalize on its new rental program, allowing hospitals to buy disposable antennas and pay a fee-per-use for using the MicroThermX system.
Read more
Dehaier Medical sets up an in-house subsidiary to further international aspirations
Dehaier Medical Systems (NSDQ:DHRM)
established a fully owned subsidiary, dubbed BreathCare, which will function as an operations center for the company’s internation-focused business, including product registration, marketing and evaluating potential M&A targets.
Read more
Acquisition of iTriage may have had another player
Aetna’s acquisition of mHealth startup Healthagen, maker of the iTriage app for smartphones, may have left athenahealth in the dust.
"Hats off to Aetna, they clearly are a fast-moving player, because they beat me to the punch," athenahealth VP of corporate development Karl Zachar said of the deal.
Read more
Covidien closes $300M buyout of superDimension
Covidien (NYSE:COV) closed the books on its $300 million buyout of superDimension, a merger initially announced in March. Read more
NxStage Medical hits a 52-week low
NxStage Medical (NSDQ:NXTM) hit a new 52-week low of $14.83 on Friday on the way to closing at $15.12, down 0.5% on the day.
Abiomed hits 52-week high
Abiomed (NSDQ:ABMD) set off a Wall Street roller coaster with its latest earnings release this week, with ABMD shares shooting up 10 in after-hours and morning trading to open at a new 52-week high of $26.17 yesterday. Trading settled down later in the day and by market’s close ABMD shares had fallen back to $23.22, down 2.2% on the day.
GPOs: Novation, HealthTrust sign deals for patient monitoring systems
Group purchasing organizations Novation and HealthTrust each signed new deals for patients monitoring system.
Novation signed with EarlySense for continuous, contact-free patient monitoring, which provides early detection of patient deterioration through continuous heart, respiratory and movement monitoring without ever touching the patient.
HealthTrust Purchasing Group signed a contract with Mindray (NYSE:MR) for its full line of physiological patient monitoring equipment, including the new V-Series modular monitor line with touch-screen interfaces.
Read more
- Mitralign raises $35M in Series D financing for percutaneous mitral valve repair systems
- Zyga Technology lands $25M in Series C round for Glyder resurfacing device
- Hamilton Thorne closes 1st tranche of private placement offering with $450k
- Proteus secures $17.5M of a hoped-for $50M for “intelligent medicine” suite of technologies
- TearScience raises $44.5M in Series C round for devices to treat chronic dry eye disease
Analysts’ ups and downs
